Introduction
Gastric cancer is a common malignancy globally and remains a disease of high morbidity and mortality (1) (2) (3) . Tumor development is an extremely complex biological process involving multiple genes, factors and stages. In some sense, cancer is a genetic disease. Therefore, understanding the molecular genetics of gastric cancer may reveal new strategies for the prevention and treatment of gastric cancer in the future (4) (5) (6) . Angiogenesis factors and various cytokines appear to be involved in tumor cell proliferation, invasion and metastasis. Midkine (MK) is a recently discovered heparin-binding growth factor with strong differentiation, mitotic and angiogenesis activity (7) (8) (9) . Vascular endothelial growth factor (VEGF) promotes vascular endothelial cell proliferation and its high expression in tumors is significantly associated with advanced disease and poor prognosis (10) (11) (12) . We investigated MK and VEGF expression levels in gastric cancer specimens by immunohistochemistry, and examined their relationship to prognostic factors of gastric cancer.
Materials and methods
Patients and tissue specimens. A total of 107 patients (80 males, 27 females; age >60 years, n=52; ≤60 years, n=55), who received surgery for gastric adenocarcinoma at the Department of Oncology, Union Hospital of Fujian Medical University in 2002, were randomly selected. Complete clinical follow-up data and paraffin-embedded gastric cancer specimens were available for all patients. In addition, paraffin-embedded normal gastric mucosa specimens from 31 patients treated during the same period served as controls. Gastric cancer patients were staged using the International Union Against Cancer (UICC) 1997 TNM staging criteria, and histological typing of the primary tumor was performed using the World Health Organization (WHO) criteria. Undifferentiated (n=7), poorly differentiated (n=33), well differentiated (n=32) and moderately differentiated (n=35) gastric adenocarcinoma, either with (n=88) or without lymph node metastasis (n=19), and either depth of invasion pT 1 + pT 2 (n=23) or pT 3 + pT 4 (n=84), was diagnosed. There were 30 patients in TNM stage I + II and 77 in TNM stage III + IV. Prior to surgery, no patients received radiotherapy or chemotherapy.
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Immunohistochemical method. Tissues were fixed with 4% formaldehyde and paraffin-embedded. Serial 5-µm sections were affixed to a number of poly-resistant acid coated glass slides, placed in a 70˚C oven for 4 h to dry, stained with VEGF monoclonal antibody using an SP immunohistochemistry kit and DAB color reagent all purchased from Fuzhou Maixin Bio-Tech. Co. (Fujian, China), and stained with MK monoclonal antibodies according to the manufacturer's instructions (SantaCruz Biotechnology, Santa Cruz, CA, USA). Phosphate-buffered saline (PBS) instead of primary antibody was used as the negative control. The positive control was provided by the company.
Evaluation of the staining reaction. Brown or brown-yellow staining signals found in the cell membrane or cytoplasm were considered to indicate MK and VEGF immunopositivity. The negative controls were unstained. The number of positive cells in 500 tumor cells was counted within 5 randomly selected high power fields (x400). Four grades were defined according to the percentage of positively stained cells: 0, no immunopositive cells; 1, <25% immunopositive cells; 2, 25-50% immunopositive cells; 3, >50% immunopositive cells. Four grades were defined according to color-staining intensity: 0, no color; 1, weak, pale yellow; 2, medium, brown; 3, strong, dark brown. The final overall score (determined by summing the two grades) was: 0-2, negative, '-'; 3-4, weakly positive, '+'; and 5-6, strongly positive, '++'. Overall scores of '+' and '++' were all considered as positive to simplify data processing.
Statistical analysis. All data were analyzed using SPSS v.11.5. Categorical variables were compared using the χ 2 test and continuous variables were compared using a t-test. The correlation between two variables was evaluated using Spearman rank correlation analysis. P<0.05 was considered to be statistically significant. Survival curves were drawn using the Kaplan-Meier method, and differences between the curves Table I . Correlation of MK or VEGF expression with clinicopathological characteristics. were tested using the log-rank test. To identify the prognostic factors of gastric cancer, a Cox regression model of multivariate analysis was used. (Table II) .
Results

MK
MK and VEGF expression was correlated with poor survival.
The 5-year survival rate of patients with MK-and VEGF-positive tumors was 25.41 and 22.65%, respectively. Both survival rates were significantly lower than those of patients with MK-or VEGF-negative tumors. Analysis using Cox's proportional hazards model with forward stepwise regression showed the independence of tumor PTNM stage (P=0.003) and of MK with VEGF co-expression (P=0.003) as prognostic factors following radical gastrectomy (Figs. 3-5 and Table III ). 
Discussion
The gene for MK was cloned by Kadomatsu et al (13) in 1988. MK and pleiotrophin (PTN) belong to a family of heparinbinding growth factors (HBGFs). Under normal conditions, the MK level is high in the embryonic period and decreases after birth. In adults, no expression is found, except in the kidney and intestinal epithelium. Previous studies have shown that MK is highly and frequently expressed in a variety of cancer tissues, demonstrating that MK may be associated with tumorigenesis and tumor growth, invasion and metastasis (14) (15) (16) (17) (18) . MK binds to complex membrane protein receptors, including protein tyrosine phosphatase ζ (PTPζ), low-density lipoprotein-related protein (LRP), anaplastic lymphoma kinase and syndecan (19, 20) . Maeda et al (21) found that chondroitin sulfate proteoglycan binds to the heparin binding site of MK. In particular, the chondroitin sulfate proteoglycan PTPζ showed marked affinity for MK. Shibata et al (22) confirmed that LRP, another component of the MK receptor, recognizes a variety of ligands, such as apolipoprotein E, and transports these ligands through endocytosis. LRP also activates α-2 macroglobulin, transports MK into cells and transfers MK into the nucleus via nucleolin (a nuclear-cytoplasmic transfer protein).
Growth of solid tumors depends on angiogenesis. Cytokines, such as MK, VEGF, BFGF and IL-8, play a role in tumor neovascularization. MK regulates proliferation, enhances fibrinolysis, has anti-apoptotic activity and induces malignant transformation. In the study by Rha et al (23) , 67% of gastric cancer cells had high MK expression. Cells expressing MK are better able to form colonies on agar gel and to stimulate growth of vascular endothelial cells. Obata et al (24) showed that serum MK levels were significantly higher in patients with gastric cancer than in healthy individuals, and significantly higher in patients with advanced gastric cancer than in patients with early-stage disease, indicating that serum MK level (compared to histological staining) more directly reflects tumor stage. Huang et al (25) reported a positive correlation of MK level in gastric cancer tissues with clinical stage and lymph node metastasis, but not with tumor size and degree of tumor differentiation, suggesting that MK could be used as an effective biological indicator for early diagnosis of gastric cancer and prediction of prognosis.
VEGF promotes endothelial cell proliferation and angiogenesis, and increases vascular permeability to serum proteins. This provides a basis for migration of endothelial cells and metastasis of tumor cells (26) . Numerous studies have confirmed that VEGF expression is high in a variety of malignant tumors. Maeda et al (27) detected VEGF expression in 129 gastric cancer samples by immunohistochemistry, and found a correlation between VEGF and tumor invasion and metastasis, suggesting that VEGF could be used as a molecular marker to evaluate the biological behavior and prognosis of gastric cancer.
In our immunohistochemical examination, MK and VEGF were highly expressed in gastric cancer tissues, but not in normal gastric mucosa. The difference in expression levels between these two tissues was significant (P= 0.00). The MK and VEGF proteins were concentrated mainly in the cytoplasm (not in the nucleus) of gastric cancer cells. There was diffuse staining of tumor tissues and some marked differences in staining distribution between tissues, including enhanced expression at the gastric tissue edges, positive staining of fibrous tissue in the extracellular matrix of gastric cancer, and positive staining of small blood vessel endothelial cells (particularly in tissues with high vascular density). These results indicate that MK and VEGF act synergistically in stimulating tumor angiogenesis in gastric cancer. MK and VEGF expression was associated with tumor size, depth of invasion, lymph node metastasis and pathological stage, but not with the age and gender of patients. Expression was significantly higher in tumors with a diameter greater than 5 cm, serosal invasion and lymph node involvement, and in patients with intermediate or advanced-stage disease (P<0.01). These results indicate that MK and VEGF act cooperatively to promote gastric cancer growth and cancer cell invasion and metastasis. We also found that the high MK and VEGF expression occurred mostly in patients with late-stage disease or poor prognosis, which is consistent with the results of Shimada et al (28) . In this study, multivariate Cox analysis showed that coincident expression of MK and VEGF, but not MK or VEGF alone, may be used as an independent prognostic factor of gastric cancer, suggesting that MK and VEGF act synergistically in gastric cancer cell proliferation, invasion and metastasis. Further studies are required to determine the specific mechanism. These studies may lead to new cancer treatments, possibly using antisense oligonucleotides to target VEGF and MK genes and gene expression (29, 30) . 
